CP Scorecard
Derived from Current Agreements, the partnering scorecard gives an instant overview of the top partnering deals in the life sciences by year.
The following article contains a snapshot of the largest deals by value for the year.
Our Current Agreements database stores and categorizes deal data dating as far back as 2000 saving you valuable time on your deal making research activities.
Searching for more deal information? Current Partnering offers the following options:
|
Top partnering deals of 2022 valued at over US$500m.
Partners | Date | Value, US$m | Subject | Termsheet |
---|---|---|---|---|
IGM Biosciences, Sanofi | Mar 2022 | 6305 | Collaboration agreement for IgM antibody agonists against oncology and immunology/inflammation targets | IGM Biosciences announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets. Engineered IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies possessing 10 binding sites compared to conventional IgG antibodies having only 2 target binding sites. IGM will receive a $ 150 million upfront payment. Sanofi has also expressed an interest in purchasing up to $100M of IGM non-voting common stock in a public financing. For each oncology target collaboration program, IGM will lead research and development activities, and assume related costs, through approval of the first biologics license application for a product directed to that oncology target by the FDA or EMA in exchange for up to $940 million in development and regulatory milestones per oncology target. After receipt of the first marketing approval for a product directed to an oncology target, Sanofi will lead all subsequent development and commercialization activities for that oncology target. For each oncology target, the companies will share profits 50:50 in certain major markets, and IGM will be eligible to receive tiered royalties on net sales in the rest of world. For each immunology/inflammation target collaboration program, IGM will lead research and development activities, and assume related costs, through the completion of Phase 1 clinical trial for up to two constructs directed to each immunology/inflammation target, after which Sanofi will be responsible for all future development and related costs, in exchange for up to $1,065 million in aggregate development and regulatory and commercial milestones per immunology/inflammation target. Following the completion of Phase 1 clinical trial for each immunology/inflammation target, Sanofi will be responsible for subsequent development activities, commercialization efforts, and related costs. IGM is eligible to receive tiered high single-digit to low-teen royalties on global net sales. |
Poseida Therapeutics, Roche | Aug 2022 | 6220 | Collaboration, option and licensing agreement for allogeneic CAR-T cell therapies for hematologic malignancies | Poseida Therapeutics has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The global collaboration covers the research and development of multiple existing and novel "off-the-shelf" cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications. Roche will receive from Poseida either exclusive rights or options to develop and commercialize a number of allogeneic CAR-T programs in Poseida's portfolio that are directed to hematologic malignancies, including P-BCMA-ALLO1, an allogeneic CAR-T for the treatment of multiple myeloma and for which a Phase 1 study is underway, and P-CD19CD20-ALLO1, an allogeneic dual CAR-T for the treatment of B-cell malignancies with an IND expected in 2023. Building on complementary expertise and capabilities, the parties will also collaborate in a research program to create and develop next-generation features and improvements for allogeneic CAR-T therapies, from which they would jointly develop additional allogeneic CAR-T product candidates directed to existing and new hematologic targets. For a subset of both the Poseida portfolio programs licensed or optioned to Roche and the parties' future collaboration programs, Poseida will conduct the Phase 1 studies and manufacture clinical materials before transitioning the programs to Roche for further development and commercialization. Roche will be solely responsible for the late-stage clinical development and global commercialization of all products that are subject to the collaboration. Poseida will receive $110 million upfront and could receive up to $110 million in near-term milestones and other payments in the next several years. In addition, Poseida is eligible to receive research, development, launch, and net sales milestones and other payments potentially up to $6 billion in aggregate value, as well as tiered net sales royalties into the low double digits, across multiple programs. |
Biocon, Viatris | Feb 2022 | 3335 | Asset purchase agreement for biosimilars assets | Biocon Biologics has entered into a definitive agreement with its partner Viatris. Biocon Biologics will acquire Viatris’ biosimilars business to create a unique fully integrated global biosimilars enterprise. Viatris will receive consideration of up to USD 3.335 billion, including cash up to USD 2.335 billion and Compulsorily Convertible Preference Shares in BBL, valued at USD 1 billion. Viatris will receive cash consideration of USD 2 billion on closing of the transaction and up to USD 335 million as additional payments expected to be paid in 2024. Additionally, upon closing of the transaction, BBL will issue USD 1 billion of Compulsorily Convertible Preference Shares to Viatris, equivalent to an equity stake of at least 12.9% in the Company, on a fully diluted basis. BBL Acquires: Viatris’ global commercial infrastructure in developed and emerging markets Viatris’ global biosimilars business with an estimated revenue of USD 875 million and EBITDA of USD 200 million for CY 2022 and estimated to exceed USD 1 billion in revenue next year Viatris’ rights in all biosimilars assets including its in-licensed portfolio and an option to acquire Viatris’ rights in bAflibercept Transition services for an expected two-year period to ensure a seamless transition with partners and continued services to patients and customers |
BioNTech, Pfizer, US Government | Jun 2022 | 3200 | Supply agreement for Omicron-adapted COVID-19 vaccines | Pfizer and BioNTech announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may include adult Omicron-adapted COVID-19 vaccines, subject to authorization from the U.S. Food and Drug Administration. The doses are planned to be delivered as soon as late summer 2022 and continue into the fourth quarter of this year. The U.S. government will pay the companies $3.2 billion upon receipt of the first 105 million doses. Under this agreement, the U.S. government also has the option to purchase up to 195 million additional doses, bringing the total number of potential doses to 300 million. |
Bristol-Myers Squibb, Century Therapeutics | Jan 2022 | 3150 | Collaboration, option, licensing and co-promotion agreement for iPSC-derived allogeneic cell therapies | Century Therapeutics and Bristol Myers Squibb announced a research collaboration and license agreement to develop and commercialize up to four induced pluripotent stem cell derived, engineered natural killer cell and / or T cell programs for hematologic malignancies and solid tumors. The first two programs include a program in acute myeloid leukemia and a program in multiple myeloma, which could incorporate either the iNK or a gamma delta iT platform. Bristol Myers Squibb has the option to add two additional programs which can be nominated subject to certain conditions agreed with Century in the agreement. Century will be responsible for development candidate discovery and preclinical development activities. Bristol Myers Squibb will be responsible for clinical development and commercialization activities subject to Century’s co-promotion rights on certain programs. Century will receive a $100 million upfront payment and Bristol Myers Squibb will make a $50 million equity investment in Century Therapeutics’ common stock at a price of $23.14 per share. Century will receive reimbursement of certain preclinical development costs for development candidates licensed by Bristol Myers Squibb, and is eligible for additional payments for future program initiations and development, regulatory, and commercial milestone payments totaling more than $3 billion across the four potential programs. Century will also receive tiered royalties as a percentage of global net sales in the high-single to low-double digits. Century may elect to co-promote the AML program and one of the additional programs in the United States for no exercise fee which will also trigger enhanced U.S. royalties. |
Bayer, Cinven | Mar 2022 | 2600 | Asset purchase agreement for environmental science professional business | Bayer and Cinven have entered into a definitive agreement regarding the sale of Bayer’s Environmental Science Professional business for a purchase price of 2.6 billion U.S. dollars. |
Adagene, Sanofi | Mar 2022 | 2517.5 | Collaboration, option and licensing agreement for masked immuno-oncology antibody candidates | Adagene announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi. Adagene will be responsible for early stage research activities to develop masked versions of Sanofi candidate antibodies, using Adagene’s SAFEbody technology. Sanofi will be solely responsible for later stage research and all clinical, product development and commercialization activities. Sanofi will make an upfront payment of $17.5 million to Adagene and will have the ability to advance two initial Sanofi antibody candidates in the collaboration, followed by an option for two additional candidates. Adagene will be eligible to receive total potential development, regulatory and commercial milestone payments of up to $2.5 billion for advancement of the candidates, which will be exclusively developed and commercialized by Sanofi. Adagene is eligible to also receive tiered royalties on global net sales of approved collaboration products. |
Biogen, Samsung Bioepis, Samsung Biologics | Jan 2022 | 2300 | Asset purchase agreement for Samsung Bioepis joint venture | Biogen have entered into an agreement whereby Samsung Biologics will acquire Biogen’s equity stake in the Samsung Bioepis joint venture for an aggregate consideration of up to USD $2.3 billion. |
Sanofi, Skyhawk Therapeutics | Jul 2022 | 2054 | Collaboration agreement for small molecules that modulate RNA splicing for challenging oncology and immunology targets | Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration agreement with Sanofi US to discover and develop novel small molecules that modulate RNA splicing for challenging oncology and immunology targets. Sanofi will pay Skyhawk $54 million upfront. Skyhawk will grant Sanofi exclusive licenses to worldwide intellectual property rights to candidates discovered and developed under the collaboration that are directed to program targets. Following DC status, Sanofi will assume responsibility for further development and commercialization. Skyhawk is also eligible to receive over $2 billion in potential milestone payments, as well as potential royalties on future sales. |
Code Biotherapeutics, Takeda Pharmaceutical | Feb 2022 | 2000 | Collaboration, option and licensing agreement for 3DNA genetic medicine delivery platform for therapies for rare diseases | Code Biotherapeutics announced a collaboration and option agreement with Takeda to leverage Code Bio’s proprietary targeted 3DNA non-viral genetic medicine delivery platform to design and develop gene therapies for rare disease indications. Takeda and Code Bio will design and develop a targeted gene therapy leveraging Code Bio’s 3DNA platform for a liver-directed rare disease program, plus conduct additional studies for central nervous system-directed rare disease programs. Takeda has the right to exercise options for an exclusive license for four programs. Code Bio will receive double-digit million dollars in upfront, near-term milestone and research funding payments. Code Bio is also eligible to receive future development and commercial milestone payments plus tiered royalties with a potential total deal value over the course of the partnership of up to $2 billion if milestones for all four programs are achieved. Takeda and Code Bio will collaborate on research activities up to candidate selection. After option exercise, Takeda will assume responsibility for further development and commercialization. |
Amgen, Generate Biomedicines | Jan 2022 | 1900 | Collaboration and licensing agreement for protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities | Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities. Amgen will pay $50 million in upfront funding for the initial five programs with a potential transaction value of $1.9 billion plus future royalties, and will have the option to nominate up to five additional programs, at additional cost. For each program, Amgen will pay up to $370 million in future milestones and royalties up to low double digits. Amgen will also participate in a future financing round for Generate. Additional terms were not disclosed. |
Bristol-Myers Squibb, GentiBio | Aug 2022 | 1900 | Collaboration and licensing agreement for engineered Treg therapies for inflammatory bowel diseases | GentiBio has entered into a collaboration with Bristol Myers Squibb to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases. The collaboration brings together GentiBio's proprietary engineered Treg platform for generating scalable, stable, highly-selective, and durable Tregs with Bristol Myers Squibb's leadership in cell therapies and immunology. During the multi-year collaboration, GentiBio will apply its modular engineered Treg platform and scalable manufacturing process to produce stable and disease-specific engineered Tregs against multiple targets. Bristol Myers Squibb will have the right to develop and advance up to three of the resulting programs into clinical trials. Bristol Myers Squibb made an undisclosed upfront cash payment to GentiBio. GentiBio is eligible to receive development and sales milestone payments of up to $1.9 billion and royalties. |
Eli Lilly, ImmunoGen | Feb 2022 | 1745.5 | Licensing agreement for camptothecin ADC platform | ImmunoGen announced a global, multi-year definitive licensing agreement whereby it granted Eli Lilly exclusive rights to research, develop, and commercialize ADCs directed to targets selected by Lilly based on ImmunoGen's novel camptothecin technology. ImmunoGen retains full rights to the camptothecin platform for all targets not covered by the Lilly license. Lilly will pay ImmunoGen an upfront payment of $13 million, reflecting initial targets selected by Lilly. Lilly may select a pre-specified number of additional targets, with ImmunoGen eligible to receive an additional $32.5 million in exercise fees if Lilly licenses the full number of targets. ImmunoGen is eligible to receive up to $1.7 billion in potential target program exercise fees and milestone payments based on the achievement of pre-specified development, regulatory, and commercial milestones. ImmunoGen is also eligible for tiered royalties as a percentage of worldwide commercial sales by Lilly. Lilly is responsible for all costs associated with research and development. |
Beam Therapeutics, Pfizer | Jan 2022 | 1650 | Collaboration, option and licensing agreement for in vivo base editing programs for range of rare diseases | Pfizer and Beam Therapeutics announced an exclusive four-year research collaboration focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. The base editing programs to be evaluated as part of the collaboration will leverage Beam’s proprietary in vivo delivery technologies, which use messenger RNA and lipid nanoparticles to deliver base editors to target organs. Combining these technologies with Pfizer’s proven experience in developing and manufacturing medicines and vaccines, this collaboration seeks to advance potentially transformative therapies for patients living with rare diseases. Beam will conduct all research activities through development candidate selection for three undisclosed targets, which are not included in Beam’s existing programs. Pfizer may opt in to exclusive, worldwide licenses to each development candidate, after which it will be responsible for all development activities, as well as potential regulatory approvals and commercialization, for each such candidate. Beam has a right to opt in, at the end of Phase 1/2 studies, upon the payment of an option exercise fee, to a global co-development and co-commercialization agreement with respect to one program licensed under the collaboration pursuant to which Pfizer and Beam would share net profits as well as development and commercialization costs in a 65%/35% ratio (Pfizer/Beam). Beam will receive an upfront payment of $300 million and, assuming Pfizer exercises its opt-in license rights for all three targets, is eligible for development, regulatory and commercial milestone payments for potential total deal consideration of up to $1.35 billion. Beam is also eligible to receive royalties on global net sales for each licensed program. The collaboration has an initial term of four years and may be extended up to one additional year. |
Ipsen, Marengo Therapeutics | Aug 2022 | 1637 | Collaboration and licensing agreement for precision immuno-oncology candidates from STAR platform | Ipsen and Marengo Therapeutics announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. The collaboration will leverage Marengo’s proprietary R&D expertise of a novel mechanism of T cell activation with Ipsen’s global oncology footprint for clinical development and commercialization. Ipsen will make an upfront payment of $45 million, together with potential payments up to a total of $1.592 billion if all milestones are met in addition to tiered sales royalty payments. Marengo will lead the preclinical development efforts and will expense related costs until the submission of an Investigational New Drug application to the U.S. FDA. Ipsen will assume responsibilities for clinical development and commercialization. |
AstraZeneca, Scorpion Therapeutics | Jan 2022 | 1575 | Collaboration, option, licensing, co-development and co-promotion agreement for precision medicines against hard-to-target cancer proteins | Scorpion Therapeutics announced a collaboration with AstraZeneca to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment. The collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular process including cell growth and survival. To overcome the challenges of targeting transcription factors and to reach underserved patient populations, this collaboration will combine Scorpion’s fully integrated discovery platform with AstraZeneca’s leadership in developing and commercializing precision medicines for cancer treatment. Scorpion will lead discovery and certain preclinical activities. AstraZeneca has the exclusive option to license worldwide rights for up to three drug candidates. AstraZeneca would be responsible for development and commercialization activities worldwide following opt-in, while Scorpion would retain the option to co-develop and co-promote up to two of these programs in the U.S. under certain conditions, including if AstraZeneca exercises three license options. Scorpion will receive an upfront cash payment of $75 million and is eligible to receive up to an additional $1.5 billion in the form of option fees and milestone payments, as well as tiered royalties on net sales ranging from mid-single digit to low-double digits. In the event Scorpion opts-in to co-developing and co-promoting a nominated program, Scorpion will participate in the operating costs and be entitled to a proportionate share of the economics in the U.S., subject to certain adjustments. |
Novartis, Precision BioSciences | Jun 2022 | 1475 | Collaboration agreement for curative treatment for disorders including sickle cell disease | Precision BioSciences has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma. Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a “safe harbor” location in the genome as a potential one-time transformative treatment option for diseases including certain hemoglobinopathies such as sickle cell disease and beta thalassemia. Precision will develop an ARCUS nuclease and conduct in vitro characterization, with Novartis then assuming responsibility for all subsequent research, development, manufacturing and commercialization activities. Novartis will receive an exclusive license to the custom ARCUS nuclease developed by Precision for Novartis to further develop as a potential in vivo treatment option for sickle cell disease and beta thalassemia. Precision will receive an upfront payment of $75 million and is eligible to receive up to an aggregate amount of approximately $1.4 billion in additional payments for future milestones. Precision is also eligible to receive certain research funding and, should Novartis successfully commercialize a therapy from the collaboration, tiered royalties ranging from the mid-single digits to low-double digits on product sales. |
GlaxoSmithKline, Mersana Therapeutics | Aug 2022 | 1460 | Option, co-development and licensing agreement for XMT-2056 | Mersana Therapeutics announced a global collaboration that provides GSK an exclusive option to co-develop and commercialize XMT-2056, an Immunosynthen ADC that targets a novel epitope of HER2. XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and in tumor cells. Mersana will receive an upfront option purchase fee of $100 million. Mersana also is eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option. Mersana has retained options to profit-share and to co-promote in the United States. If it exercises its profit-share option, Mersana will be eligible to receive tiered royalties on net sales outside of the United States. If Mersana does not elect to profit-share, it is eligible to receive double-digit tiered royalties on global net sales. |
Astellas Pharma, Sutro Biopharma | Jun 2022 | 1357.5 | Collaboration, licensing and option agreement for immunostimulatory antibody-drug conjugates | Astellas Pharma and Sutro Biopharma announced a worldwide, strategic collaboration and licensing agreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates. The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro’s ability to engineer complex conjugated antibodies, and Astellas’ global oncology R&D expertise. This strategic partnership will engage in the development of iADCs, a next generation modality with the potential for effective and efficient approaches for treatment of cold tumors so as to bring new drug therapies to patients who do not respond to existing therapies. An iADC, which combines an antibody with a small molecule compound that induces immunogenic cell death*2 in addition to an immune activating molecule, has the potential to boost the anti-cancer action. This partnership will enable Astellas and Sutro to mutually leverage strengths in their respective fields to accelerate iADC development for three distinct biological targets; Sutro will engage in research and preclinical studies to identify candidate compounds and then Astellas will pursue clinical development. Sutro has advanced technologies for linking drugs to antibodies and proprietary component parts, including candidate antibodies and linkable cytotoxins and immunostimulatory molecules. For development of iADCs, Astellas will utilize the strength of its global R&D and commercialization capabilities in the area of antibodies and the small molecular components. These iADCs may have the potential to provide new therapeutic options for treatment of cancers for which no broadly effective therapy is currently available. Under the terms of the agreement, Sutro will receive an upfront cash payment of US$90 million to develop iADCs for three biological targets and may be eligible to receive up to US$422.5 million in development, regulatory and commercial milestones for each product candidate, and tiered royalties ranging from low double-digit to mid-teens on worldwide sales of any commercial products that may result from the collaboration, subject to Sutro’s cost and profit sharing option for the United States. Sutro has the option to share in the costs and profits for developing and commercializing product candidates in the United States. If Sutro exercises this option for a particular product candidate, Astellas and Sutro will equally share the costs of such co-development and co-commercialization, with the resulting profits/losses from co-commercialization also shared equally in the United States. |
Royalty Pharma, Theravance Biopharma | Jul 2022 | 1350 | Royalty financing agreement for TRELEGY ELLIPTA | Theravance Biopharma has entered into a definitive agreement to sell all of its units in Theravance Respiratory Company, representing its 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK's TRELEGY ELLIPTA to Royalty Pharma for over $1.5 billion in potential total value. The transaction is intended to provide near-, mid- and long-term value to the Company with an upfront cash payment of approximately $1.1 billion, up to $250 million in additional milestone payments contingent on the achievement of certain TRELEGY net sales thresholds between 2023 and 2026 and outer year royalties to the Company providing an opportunity to receive an estimated NPV of approximately $200 million. |
Repare Therapeutics, Roche | Jun 2022 | 1325 | Collaboration, licensing, option and co-promotion agreement for Camonsertib (RP-3500) | Repare Therapeutics has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (Ataxia-Telangiectasia mutated kinase). Roche will assume development of camonsertib with the potential to expand development into additional tumors and multiple combination studies. Repare will receive a $125 million upfront payment, and is eligible to receive up to $1.2 billion in potential clinical, regulatory, commercial and sales milestones, including up to $55 million in potential near-term payments, and royalties on global net sales ranging from high-single-digits to high-teens. The collaboration also provides Repare with the ability to opt-in to a 50/50 U.S. co-development and profit share arrangement, including participation in U.S. co-promotion if U.S. regulatory approval is received. If Repare chooses to exercise its co-development and profit share option, it will continue to be eligible to receive certain clinical, regulatory, commercial and sales milestone payments, in addition to full ex-U.S. royalties. |
Amphista Therapeutics, Bristol-Myers Squibb | May 2022 | 1280 | Collaboration and licensing agreement for targeted protein degradation therapeutics | Amphista Therapeutics announced a strategic collaboration and license agreement with Bristol-Myers Squibb. Bristol Myers Squibb and Amphista will work collaboratively to discover and develop small molecule protein degraders. Bristol Myers Squibb will be granted a global exclusive license to the degraders developed and will be responsible for further development and commercialization activities. Amphista will receive a $30 million upfront payment, the potential for up to $1.25 billion in performance-based milestone payments and payment for a limited expansion of the collaboration, as well as royalties on global net sales of products. |
Abbvie, Sosei | Aug 2022 | 1280 | Collaboration, option and licensing agreement for small molecules that modulate novel G protein-coupled receptor targets associated with neurological disease | Sosei and AbbVie have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor targets associated with neurological disease. The new agreement will leverage Sosei Heptares’ StaR technology and structure-based drug design platform and AbbVie’s extensive neuroscience and disease area expertise. The agreement expands the breadth of the ongoing collaboration between Sosei Heptares and AbbVie, building on the first multi-target discovery agreement signed between the companies in June 2020, which is focused on the inflammatory and autoimmune disease areas. Sosei Heptares will conduct and fund R&D activities through the completion of Investigational New Drug-enabling studies. AbbVie has the exclusive option to license up to three programs at this stage and will have responsibility for clinical, regulatory and commercial development thereafter. Sosei Heptares receives an upfront payment of US$40 million on signing and is eligible to receive up to US$40 million in near-term research milestone payments expected over the next three years, as well as further potential option, development and commercial milestones totalling up to US$1.2 billion, plus tiered royalties on global sales. |
Jazz Pharmaceuticals, Werewolf Therapeutics | Apr 2022 | 1275 | Collaboration and licensing agreement for WTX-613 | Jazz Pharmaceuticals and Werewolf Therapeutics have entered into a licensing agreement under which Jazz has acquired exclusive global development and commercialization rights to Werewolf's investigational WTX-613, a differentiated, conditionally-activated interferon alpha (IFNα) INDUKINE molecule. Jazz has secured exclusive global rights to WTX-613. Jazz will make an upfront payment of $15 million to Werewolf, and Werewolf is eligible to receive development, regulatory and commercial milestone payments of up to $1.26 billion. Werewolf is eligible to receive a tiered, mid-single-digit percentage royalty on net sales of WTX-613. |
Gilead Sciences, ViiV Healthcare | Feb 2022 | 1250 | Settlement and licensing agreement for Bictegravir patent | Gilead Sciences has reached a global resolution with ViiV Healthcare for all pending or potential claims related to Gilead’s sales of the HIV treatment Biktarvy (bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg tablets). ViiV Healthcare will dismiss all pending lawsuits relating to bictegravir, the novel compound in Biktarvy. Gilead will make a one-time payment of $1.25 billion and an ongoing royalty payment of 3% until 2027 on future sales of Biktarvy and on the bictegravir component of any future bictegravir-containing products sold in the U.S. |
Elevation Oncology | Jul 2022 | 1175 | Licensing agreement for EO-3021 (SYSA1801) | Elevation Oncology has entered into an exclusive license agreement with CSPC Megalith Biopharmaceutical to develop and commercialize EO-3021 (SYSA1801), a differentiated, clinical stage antibody drug conjugate targeting Claudin18.2, in all global territories outside Greater China (mainland China, Hong Kong, Macau and Taiwan). SYSA1801 is currently being evaluated by CSPC in a Phase 1, dose-escalation clinical trial in China. Elevation Oncology expects to initiate a Phase 1 clinical trial evaluating EO-3021 in the U.S. in 2023. Elevation Oncology will develop and commercialize EO-3021 in all global territories outside of Greater China. CSPC will receive a one-time, upfront payment of $27 million. CSPC will also be eligible to receive up to $148 million in potential development and regulatory milestone payments and up to $1.0 billion in potential commercial milestone payments plus royalties on net sales. |
Jazz Pharmaceuticals, Sumitomo Pharmaceuticals | May 2022 | 1140 | Licensing agreement for DSP-0187 | Jazz Pharmaceuticals and Sumitomo Pharma have entered into an exclusive licensing agreement under which Jazz has acquired development and commercialization rights in the United States, Europe and other territories for Sumitomo Pharma's investigational DSP-0187, a potent, highly selective oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy, idiopathic hypersomnia and other sleep disorders. Jazz has designated this molecule JZP441. Jazz will receive an exclusive license to develop and commercialize DSP-0187 throughout the world except for Japan, China and certain other Asia/Pacific countries and regions, where Sumitomo Pharma will retain all development and commercialization rights. Sumitomo Pharma will receive an upfront payment of $50 million, and is eligible to receive development, regulatory and commercial milestone payments of up to $1.09 billion. Pending approval, Sumitomo Pharma is eligible to receive a tiered, low double-digit royalty on Jazz's net sales of DSP-0187. |
Bristol-Myers Squibb, Volastra Therapeutics | Mar 2022 | 1130 | Collaboration and licensing agreement for drug discovery using CINtech platform | Volastra Therapeutics announced a collaboration with Bristol Myers Squibb to discover, develop and commercialize new medicines. The multi-year collaboration will leverage Volastra’s proprietary CINtech platform, to identify CIN-related, synthetic lethal targets as drug candidates. Volastra will be responsible for conducting various activities for undisclosed targets. For select targets, Volastra will conduct all research activities through development candidate selection and Bristol Myers Squibb may take on the responsibilities for all subsequent development, regulatory and commercialization activities of the development candidates under an exclusive worldwide license. Volastra will receive $30 million in an upfront payment and will also be eligible to receive up to $1.1 billion in development, regulatory and commercial milestone payments. Volastra is entitled to receive royalties on net global sales of any product commercialized by Bristol Myers Squibb resulting from the collaboration. |
Cerevance, Merck and Co | Aug 2022 | 1125 | Collaboration and licensing agreement for discovery of novel targets in Alzheimer’s disease | Cerevance announced a multi-year strategic research collaboration with Merck to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform. Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration. Cerevance will receive a $25 million upfront payment and is eligible to receive development and commercial milestone payments totaling approximately $1.1B, in addition to potential royalties on sales of approved products derived from the collaboration. |
ABL Bio, Sanofi | Jan 2022 | 1060 | Collaboration and licensing agreement for ABL301 | ABL Biotechnologies announced an exclusive collaboration and worldwide license agreement with SANOFI to develop and commercialize ABL301, a pre-clinical stage bispecific antibody targeting alpha-synuclein and IGF1R to treat Parkinson's disease and other potential indications with enhanced blood-brain barrier penetration. ABL will receive $75 million in upfront payments. ABL is eligible to receive up to $985 million based on the achievement of predefined development, regulatory and commercialization milestones, including $45 million in near-term milestones. ABL is also eligible to receive royalties on net sales if the product from the collaboration is commercialized. The transaction will become effective after customary closing conditions are met, such as the HSR clearance. SANOFI will receive worldwide exclusive development and commercialization rights to ABL301. Meanwhile, ABL will lead the preclinical development and Phase 1 clinical trial of ABL301. Thereafter, SANOFI will be responsible for further clinical development, regulatory approval and commercialization of ABL301 worldwide. |
Menarini, NewAmsterdam Pharma | Jun 2022 | 1049.9 | Licensing agreement for obicetrapib | NewAmsterdam Pharma and the Menarini Group announced an exclusive license agreement for the commercialization of obicetrapib, if approved, in Europe, either as a monotherapy or as part of a fixed dose combination with ezetimibe, for cardiovascular diseases. Obicetrapib is NewAmsterdam’s next-generation oral, low-dose and once-daily cholesteryl ester transfer protein inhibitor therapeutic candidate, for which a promising safety and efficacy profile as an LDL-lowering adjunct to maximally tolerated statin therapy in patients with dyslipidemia has been observed through Phase 2b trials. NewAmsterdam will retain all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer’s disease. NewAmsterdam will receive an upfront payment of €115 million, as well as €27.5 million in committed R&D funding, for a total of €142.5 million in committed consideration. NewAmsterdam will be eligible to receive up to €863 million in potential clinical, regulatory and commercial milestones, bringing the total potential deal value to €1,005.5 million. Menarini will pay NewAmsterdam tiered double-digit percentage royalties from the teens to mid-twenties on net sales of obicetrapib in Europe. NewAmsterdam will be responsible for further clinical development of obicetrapib and the parties will cooperate in regulatory activities to secure approval for the product. Menarini will be responsible for all commercialization activities in the licensed territory. |
Bayer, Mammoth Biosciences | Jan 2022 | 1040 | Collaboration, option and licensing agreement for novel gene editing technology | Bayer and Mammoth Biosciences announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. Mammoth Biosciences’ groundbreaking gene-editing technology is a key enabling technology, as well as a stand-alone therapeutic modality. It will significantly enhance Bayer’s efforts to develop transformative therapies for patients faster and strengthen the company’s recently established new cell and gene therapy platform. Under the terms of the agreement the two companies will start their collaboration with a focus on liver-targeted diseases. Mammoth Biosciences will receive an upfront payment of USD 40 million and is eligible to receive target option exercise fees as well as potential future payments in the magnitude of more than one billion USD upon successful achievement of certain research, development, and commercial milestones across five preselected in vivo indications with a first focus on liver-targeted diseases. Bayer will pay research funding and tiered royalties up to low double-digit percentage of net sales. The companies are also exploring work on ex vivo projects on a nonexclusive basis. |
Janssen Biotech, Mersana Therapeutics | Feb 2022 | 1040 | Research and licensing agreement for antibody-drug conjugates targeting cancers | Mersana Therapeutics announced a research collaboration and license agreement with Janssen Biotech to discover novel ADCs for three targets. Janssen will provide proprietary antibodies for three targets. Mersana will apply its expertise and its proprietary Dolasynthen platform to discover novel ADC product candidates. Mersana may leverage Synaffix’s GlycoConnect technology as its preferred site-specific ADC bioconjugation technology. Mersana will collaborate with Janssen on target candidates during preclinical development, with Janssen being solely responsible for clinical development and commercialization. Mersana will receive an upfront payment of $40 million. Mersana is eligible to receive reimbursement of certain costs as well as more than $1 billion in potential milestone payments, plus mid-single-digit to low double-digit percentage royalties on worldwide net sales of ADCs against the selected targets. |
Dren Bio, Pfizer | Jan 2022 | 1025 | Research and licensing agreement for bispecific antibodies for select oncology targets using targeted myeloid engager and phagocytosis platform | Dren Bio has entered into a research collaboration and license agreement with Pfizer. The strategic collaboration will focus on the discovery and development of therapeutic bispecific antibodies for select oncology targets using Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform. Pfizer made an upfront cash payment of $25 million to Dren Bio, with the Company eligible to potentially receive more than $1 billion of cash in total, including payments for the achievement of future development, regulatory, and commercial milestones. Dren Bio and Pfizer will work together to advance the selected oncology target programs through clinical candidate selection, at which point Pfizer will assume full responsibility for all remaining development, manufacturing, regulatory and commercialization activities. For each target-specific product that is globally licensed by Pfizer, Dren Bio will be eligible to receive tiered royalties on all future net sales during the term of the Agreement. Additionally, under the terms of the agreement, Pfizer also has the right to reserve and subsequently nominate additional oncology targets to license from Dren Bio, subject to additional cash payments and future royalties. Excluding products developed for targets licensed to Pfizer, Dren Bio will retain exclusive global rights for the platform including all other therapeutic targets currently in development as part of its own internal pipeline. |
HIBio, MorphoSys | Jun 2022 | 1015 | Licensing agreement for felzartamab and MOR210 | MorphoSys and Human Immunology Biosciences entered into an equity participation agreement and license agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody. HIBio will obtain exclusive rights to develop and commercialize felzartamab and MOR210 across all indications worldwide, with the exception of Greater China for felzartamab and Greater China and South Korea for MOR210. MorphoSys will receive a 15% equity stake in HIBio, along with certain equity earn-in provisions and standard investment rights. MorphoSys will also be represented as a member of HIBio’s Board of Directors. On achievement of development, regulatory and commercial milestones, MorphoSys will be eligible to receive payments from HIBio of up to $1 billion across both programs, in addition to tiered, single- to low double-digit royalties on net sales of felzartamab and MOR210 and will be compensated for ongoing program expenses. HIBio will assume full responsibility for future development and commercialization expenses. MorphoSys also receives an upfront payment of $15 million for MOR210. |
Avista Therapeutics, Roche | Jul 2022 | 1007.5 | Development and licensing agreement for AAV gene therapy vectors for ocular diseases | Avista Therapeutics announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes. The partnership aims to apply Avista’s single-cell adeno-associated virus engineering (scAAVengr) platform technology to develop intravitreal AAV capsids matching a capsid profile defined by Roche. Roche has the right to evaluate and license novel capsids from Avista, and will be responsible for conducting preclinical, clinical and commercialization activities for gene therapy programs using these novel capsids, which will be distinct from Avista’s internal pipeline. Avista will receive an upfront payment of $7.5 million and, if successful, is eligible to receive additional payments during the research phase of the partnership, as well as clinical and sales milestone payments and royalties for resulting products with a total potential deal value that may exceed $1 billion. |
Eli Lilly, Evotec | Jan 2022 | 1000 | Collaboration agreement for drug discovery in metabolic diseases with a focus on kidney diseases and diabetes | Evotec has entered into a drug discovery collaboration with Eli Lilly in the field of metabolic diseases with a focus on kidney diseases and diabetes. The collaboration leverages Evotec's extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database, to identify and validate promising novel targets for therapeutic intervention. Evotec will be responsible for the discovery of potential drug candidates for the treatment of diabetes and chronic kidney diseases from targets identified by Lilly or by Evotec. Lilly reserves the right to select up to five programmes developed within this partnership and to continue with any subsequent development, clinical validation and commercialisation. The collaboration initially runs for a term of three years. In addition to an undisclosed upfront payment, Evotec will be eligible to receive success-based discovery development, regulatory and commercial milestone payments of up to US$ 180 m per programme, as well as tiered royalties on net sales of any products resulting from the collaboration, for a potential overall value up to US$ 1 bn. |
Janssen Pharmaceutica NV, Remix Therapeutics | Feb 2022 | 1000 | Collaboration, option and licensing agreement for small molecule therapeutics using REMaster drug discovery platform to modulate RNA processing | Remix Therapeutics announced a strategic collaboration with Janssen Pharmaceutica for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform. Remix will receive an initial payment of $45 million in cash for upfront and research funding, and may also receive preclinical, clinical, commercial, and sales milestone payments and tiered royalties for any resulting products. Janssen will have exclusive rights to three specific targets with applications in immunology and oncology. Remix will have the ability to opt into a portion of the costs of clinical development on one program in exchange for higher royalties. Remix is eligible to receive total payments potentially exceeding $1 billion, subject to regulatory approvals and other conditions. |
Amphista Therapeutics, Merck and Co | May 2022 | 1000 | Collaboration agreement for targeted protein degradation therapeutics | Amphista Therapeutics announced a strategic collaboration with Merck Healthcare. Merck and Amphista will work collaboratively to discover and develop small molecule protein degraders for an initial three targets in oncology and immunology indications. Amphista will receive an upfront payment, R&D funding and success-based milestone payments of up to €893.5 million ($1.0 billion*) as well as royalties in the mid-single digit range. |
Regeneron Pharmaceuticals, Sanofi | Jun 2022 | 1000 | Licensing agreement for Libtayo | Regeneron Pharmaceuticals announced its intent to purchase Sanofi's stake in the Regeneron and Sanofi collaboration on Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization and manufacturing rights to the medicine. The transaction is subject to merger control clearance outside the United States and is expected to close in the third quarter of 2022. Once the transaction has closed, Regeneron will record 100% of global net sales and expenses for the Libtayo program. Regeneron and Sanofi entered into the Immuno-oncology License and Collaboration Agreement in 2015. Pursuant to this agreement, the companies currently split Libtayo's worldwide operating profits equally and co-commercialize Libtayo in the US, with Sanofi solely responsible for commercialization outside the US. Sanofi will transfer the rights to develop, commercialize and manufacture Libtayo entirely to Regeneron, on a worldwide basis, over the course of a defined transition period. Upon closing of the transaction, Regeneron will make an upfront payment of $900 million to Sanofi, which will be entitled to receive an 11% royalty on worldwide net sales of Libtayo. Sanofi will also be entitled to a $100 million regulatory milestone payment upon the first approval by either the FDA or European Commission of Libtayo in combination with chemotherapy for first-line treatment of certain patients with NSCLC, as well as sales-related milestone payments of up to $100 million in total over the next two years. Regeneron will accelerate reimbursement of the development balance associated with Regeneron and Sanofi's separate Antibody Collaboration. Regeneron will increase from 10% to 20% the share of its profits that are paid to Sanofi to reimburse Sanofi-funded development expenses, until Regeneron's share of the total cumulative development costs incurred under the collaboration has been reached. |
ACADIA Pharmaceuticals, Stoke Therapeutics | Jan 2022 | 967 | Collaboration and licenisng agreement for multiple RNA-based treatments for genetic neurodevelopmental diseases | Acadia Pharmaceuticals and Stoke Therapeutics have entered a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The collaboration includes SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of mutual interest. Stoke will receive an upfront payment of $60 million from Acadia and is eligible to receive up to $907 million in milestones as well as royalties on future sales. For the SYNGAP1 program, the two companies will jointly share global research, development and commercialization responsibilities and share 50/50 in all worldwide costs and future profits. Stoke is eligible to receive potential development, regulatory, first commercial sales and sales milestones. For the Rett syndrome (MECP2) and the undisclosed neurodevelopmental program, Stoke will lead research and pre-clinical development activities, while Acadia will lead clinical development and commercialization activities. Acadia will fully fund the research and pre-clinical development activities related to these two targets and Stoke is eligible to receive potential development, regulatory, first commercial sales and sales milestones as well as tiered royalty payments on worldwide sales starting in the mid-single digit range and escalating to the mid-teens based on revenue levels. |
Kelun-Biotech Biopharmaceutical, MSD | Jul 2022 | 936 | Collaboration and licensing agreement for antibody drug conjugate for treatment of solid tumors | Kelun-Biotech has entered into a collaboration and exclusive license agreement with MSD to develop an investigational antibody drug conjugate for the treatment of solid tumors. Kelun-Biotech has granted MSD global, exclusive rights to develop, manufacture and commercialize an investigational ADC. Kelun-Biotech and MSD will also collaborate on the early clinical development of the investigational ADC. Kelun-Biotech will receive an upfront payment of $35mm and is eligible to receive future development, approval and commercial milestone payments totaling up to $901mm, plus tiered royalties on net sales. |
Heidelberg Pharma, Huadong Medicine | Feb 2022 | 930 | Licensing agreement for | Heidelberg Pharma and Huadong Medicine have entered into a strategic partnership with the signing of an exclusive licensing agreement as well as an investment agreement. The agreements were concluded with wholly owned subsidiaries of Huadong, one of the leading pharmaceutical companies in China with a focus on oncology and ADC research, development and commercialization. Heidelberg Pharma has granted Huadong exclusive development and commercialization rights for HDP-101 (BCMA-ATAC) and HDP-103 (PSMA-ATAC) for Asia 1 and is eligible to receive an upfront payment of USD 20 million (EUR 17.5 million) and milestone payments of up to USD 449 million (EUR 400 million), as well as tiered royalties ranging from single to low double digit percentages for each candidate. Heidelberg Pharma has granted Huadong an exclusive option for the pre-IND research candidates HDP-102 (CD37-ATAC) and HDP-104 (undisclosed target) in Asia 1 with a total deal value of up to USD 461 million (EUR 410 million), plus tiered royalties ranging from single to low double digit percentages for each candidate. Huadong also has right of first negotiation to license the next two ATAC (R) candidates for Asia 1. Huadong becomes the strategic partner in Asia for Heidelberg Pharma's product development. |
Blueprint Medicines, Sixth Street | Jun 2022 | 910 | Royalty financing agreement for AYVAKIT/AYVAKYT and BLU-263 | Blueprint Medicines announced strategic financing collaboration with Sixth Street. The agreement with Sixth Street has three parts: $250 million cash upfront in exchange for future AYVAKIT/AYVAKYT and BLU-263 royalties at a rate of 9.75 percent subject to an annual cap of $900 million in net sales and a cumulative cap of 1.45 times invested capital; Up to $400 million in a senior secured credit facility, of which Blueprint Medicines will draw $150 million initially with an additional $250 million available in delayed draw tranches at Blueprint Medicines' election; and $260 million in a potential credit facility to support buy-side business development opportunities, subject to mutual agreement between Sixth Street and Blueprint Medicines. |
BridgeBio Pharma, Bristol-Myers Squibb | May 2022 | 905 | Licensing and option agreement for BBP-398 | BridgeBio Pharma announced an exclusive license with Bristol-Myers Squibb to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in the low- to mid-teens. BridgeBio will retain the option to acquire higher royalties in the United States in connection with funding a portion of development costs upon the initiation of registrational studies. Based on the terms of the agreement, BridgeBio will continue to lead its ongoing Phase 1 monotherapy and combination therapy trials. Bristol Myers Squibb will lead and fund all other development and commercial activities. |
Cook Medical, Cooper Companies | Feb 2022 | 875 | Asset purchase agreement for reproductive health business | Cook Medical signed a letter of intent with CooperCompanies to sell the entirety of Cook’s Reproductive Health business within the MedSurg division. CooperCompanies will pay $875 million comprised of $675 million at closing and $200 million paid in four $50 million annual installments. |
Astellas Pharma, GO Therapeutics, Xyphos Biosciences | Jun 2022 | 783.5 | Research and licensing agreement for antibodies for immuno-oncology | Astellas Pharma and GO Therapeutics announced that Xyphos Biosciences and GO have entered into a strategic research collaboration and license agreement to develop novel Immuno-Oncology therapeutics. Under the terms of the agreement, the two companies will collaborate exclusively to identify novel antibodies with high affinity to two different glycoprotein targets and apply these antibodies to a range of therapeutic modalities. GO will lead the collaboration to discover high-affinity antibodies against the two targets, and Astellas will be responsible for research activities, clinical development and commercialization of the therapeutics derived from the antibodies provided by GO. Xyphos will pay GO Therapeutics US$20.5 million in upfront cash. Milestone and contingency payments could total up to another US$763 million. |
Alexion Pharmaceuticals, AstraZeneca, Neurimmune Therapeutics | Jan 2022 | 760 | Collaboration and licensing agreement for NI006 | Neurimmune has entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca's Rare Disease group, to develop NI006, an investigational human monoclonal antibody specifically targeting misfolded transthyretin. NI006 is currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Alexion will be granted an exclusive, worldwide license to develop, manufacture and commercialize Neurimmune's ATTR clinical asset NI006. Neurimmune will receive an upfront payment of $30 million with the potential for additional contingent milestone payments of up to $730 million payable upon achievement of certain development, regulatory and commercial milestones, as well as low-to-mid teen royalties on net sales of any approved medicine resulting from the collaboration. Neurimmune will continue to be responsible for completion of the current Phase 1b clinical study on behalf of Alexion. Alexion will be responsible for further clinical development, manufacturing, and commercialization. |
Capricor Therapeutics, Nippon Shinyaku | Jan 2022 | 735 | Licensing and distribution agreement for CAP-1002 | Capricor Therapeutics has entered into a partnership with Nippon Shinyaku for the exclusive commercialization and distribution in the United States of Capricor’s lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy. Capricor will be responsible for the conduct of HOPE-3 as well as the manufacturing of CAP-1002. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in the United States. Capricor will sell commercial product to Nippon Shinyaku and in addition will receive a meaningful, double-digit share of product revenue and additional development and sales-based milestone payments. Capricor will receive an upfront payment of $30 million with potential additional milestone payments of up to $705 million. |
Alectos Therapeutics, Biogen | Jun 2022 | 722.5 | Collaboration and licensing agreement for AL01811 | Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and commercialize a novel preclinical selective GBA2 inhibitor, AL01811, which has first-in-class potential as an oral disease modifying treatment for patients with Parkinson’s disease. This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders. Biogen will make an upfront payment of $15 million to Alectos Therapeutics for an exclusive global license to AL01811 and additional unnamed backup molecules. Alectos is eligible to receive up to $77.5M in potential development payments and $630M in potential commercial payments should the collaboration achieve certain milestones. Alectos is also eligible to receive tiered royalties in the high-single-digits to mid-teens. Moving forward, both companies will collaborate on preclinical activities for AL01811 and, once AL01811 is advanced to the clinic, Biogen will assume sole responsibility for all development, regulatory, manufacturing, and commercial activities and costs. |
Eli Lilly, Lilly Institute for Genetic Medicine | Feb 2022 | 700 | Spin out agreement for Lilly Institute for Genetic Medicine | Eli Lilly announced the launch of the Lilly Institute for Genetic Medicine and an investment of approximately $700 million to establish a state-of-the-art facility at a new site in the Boston Seaport. This investment – part of the company's strategy to advance RNA based therapeutics – builds on the 2020 acquisition and rapid expansion of Prevail Therapeutics, a gene therapy pioneer based in New York City. Working together, researchers in both Boston and New York will leverage promising RNA and DNA-based technologies to develop therapies with the potential to treat or prevent diseases in a manner that is challenging or not possible with traditional medicines. |
Genentech, Kiniksa Pharmaceuticals | Aug 2022 | 700 | Licensing agreement for vixarelimab | Kiniksa Pharmaceuticals announced a global license agreement with Roche and Genentech for the rights to develop and commercialize vixarelimab, a fully human monoclonal antibody targeting oncostatin M receptor beta (OSMRβ). Kiniksa will receive $100 million in upfront and near-term payments, and is eligible to receive up to approximately $600 million in certain clinical, regulatory, and sales-based milestones, before fulfilling upstream financial obligations. Kiniksa is also eligible to receive royalties on annual net sales. Genentech will obtain rights for the development and commercialization of vixarelimab. |
Eli Lilly, Genesis Therapeutics | May 2022 | 670 | Collaboration agreement for therapies using genesis molecular AI platform | Genesis Therapeutics has entered into a strategic collaboration with Eli Lilly to discover novel therapies for up to five targets across a range of therapeutic areas. The collaboration will deploy Genesis’ pioneering AI drug discovery platform, which combines 3D structure-aware deep neural networks with cutting-edge molecular simulation. Genesis’ field-leading machine learning models will be utilized by joint teams of engineers and scientists from Genesis and Lilly as they drive toward first-in-class and best-in-class drug candidates. Genesis will partner with Lilly on three initial targets and will receive an upfront payment of $20 million. Lilly will have the option to nominate two more targets for an additional nomination payment per target. Genesis will be eligible to receive up to $670 million total in upfront; target nomination; and preclinical, development, regulatory and sales milestone payments. Genesis is also eligible to receive royalties on net sales. |
Huadong Medicine, Kiniksa Pharmaceuticals | Feb 2022 | 662 | Collaboration and licensing agreement for ARCALYST and mavrilimumab | Kiniksa Pharmaceuticals and Hangzhou Zhongmei Huadong Pharmaceutical, a wholly-owned subsidiary of Huadong Medicine announced a strategic collaboration to develop and commercialize Kiniksa’s ARCALYST and mavrilimumab in the Asia Pacific Region. Kiniksa will receive $22 million upfront and is eligible to receive up to approximately $640 million in specified development, regulatory and sales-based milestones. Kiniksa is also eligible to receive tiered royalties ranging from the low-teens to the low-twenties on annual net sales. Huadong Medicine will obtain exclusive rights and responsibility for the development and commercialization of ARCALYST and mavrilimumab in the Asia Pacific Region including Greater China, South Korea, Australia, and 18 other countries, but excluding Japan. Kiniksa will otherwise retain all existing development and commercialization rights for both assets. |
Blueprint Medicines, Proteovant Therapeutics | Feb 2022 | 652 | Collaboration, option, licensing and co-promotion agreement for targeted protein degrader therapies | Blueprint Medicines and Proteovant Therapeutics announced a strategic collaboration to advance novel targeted protein degrader therapies to address important areas of medical need. The collaboration will bring together Proteovant's Artificial Intelligence -enhanced targeted protein degradation platform and Blueprint Medicine's precision medicine expertise to discover novel targeted protein degraders. The companies will jointly research important targets and advance up to two novel protein degrader therapies into development candidates. As a core part of the collaboration, Proteovant's exclusive partner for TPD, VantAI, will deploy its leading AI technologies for degrader generation and optimization. Upon designation of a clinical development candidate, Blueprint Medicines has the exclusive option to develop and commercialize products resulting from the collaboration. Proteovant has the option to co-develop and co-commercialize the second of the two Blueprint Medicines-optioned programs in the U.S. Proteovant will receive a $20 million upfront payment and will be eligible to receive up to an additional $632 million in potential research, development, regulatory and commercialization milestone payments plus tiered royalties from mid- to high-single digits on net sales on the first two program targets, subject to adjustment in specified circumstances. Of the total contingent payments, up to $105 million would be preclinical, clinical development and regulatory milestones and up to $527 million would be approval and sales milestones. Each company will be responsible for its own costs under the research plan. Should Proteovant opt in to the second program, the parties will split profits and losses of that program equally in the U.S. along with development costs and the milestone payments for the program will be reduced accordingly. Proteovant will be eligible to receive milestone payments and royalties on ex-U.S. sales. In addition, the partners may jointly extend the collaboration, with the same structure and financial terms, to two additional program targets through additional funding by Blueprint Medicines. |
AbSci, Merck and Co | Jan 2022 | 610 | Collaboration, option and licensing agreement for AI-powered Integrated Drug Creation platform | Absci has entered into a research collaboration with Merck using Absci’s AI-powered Integrated Drug Creation Platform. Absci will deploy its Bionic Protein non-standard amino acid technology to produce enzymes tailored to Merck’s biomanufacturing applications and receive an upfront and certain other milestone payments. Merck has the option to nominate up to three targets and enter into a drug discovery collaboration agreement, and Absci would then be eligible to receive up to $610 million in upfront fees and milestone payments for all three targets, as well as research funding and tiered royalties on sales. |
Macrogenics, Synaffix | Feb 2022 | 586 | Licensing and option agreement for GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, as well as select toxSYN linker-payloads (SYNtecan E, SYNeamicin D and SYNeamicin G) | Synaffix has entered into a technology agreement with MacroGenics. MacroGenics will gain access to Synaffix's clinical stage GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, as well as select toxSYN linker-payloads (SYNtecan E, SYNeamicin D and SYNeamicin G), each designed to enable ADCs with best-in-class efficacy and tolerability. These will be combined with MacroGenics' proprietary antibody and bispecific DART antibody platform technologies to generate next generation ADCs. Synaffix will be eligible to receive up to $586 million in payments spanning upfront and milestone payments across three programs plus royalties on commercial sales. The license rights of MacroGenics for each program will be designated as exclusive or non-exclusive to each program's antibody target (or to the combination of two targets, if bispecific). The first program will commence at signature, with the option to expand the collaboration to a further two programs by March 2023. MacroGenics will be responsible for research, development, manufacturing and commercialization of the ADCs. Synaffix will support MacroGenics' research activities and be responsible for the manufacturing of components that are specifically related to its proprietary GlycoConnect and HydraSpace technologies and the toxSYN linker-payloads. |
Merck and Co, Proxygen | Jun 2022 | 554 | Collaboration and licensing agreement for molecular glue degraders | Proxygen has entered into a strategic multi-year research collaboration and license agreement with Merck & Co. Proxygen is eligible to receive up to €495 million ($554 million at the average USD/EUR FX rate of Q1 2022) in continuous R&D funding, upfront and success-based pre-clinical, clinical, regulatory, and commercial milestones, as well as additional royalty payments. Under the terms of the agreement, the companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage. |
Leidos, National Institute of Allergy and Infectious Diseases | Mar 2022 | 545 | Contract service agreement for biomedical research | Leidos was awarded a new prime contract to provide biomedical preclinical and development capabilities to support the National Institute of Allergy and Infectious Diseases. The seven-year, multi-award, indefinite delivery/indefinite quantity contract has an approximate value of up to $545 million across all task areas to be engaged on this program. This project will be funded in whole or in part with federal funds from the NIAID, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021D00030. |
Abbvie, iSTAR Medical | Jul 2022 | 535 | Development and option agreement for MINIject device device for patients with glaucoma | AbbVie and iSTAR Medical announced a strategic transaction to further develop and commercialize iSTAR Medical's MINIject device, a minimally invasive glaucoma surgical device for patients with glaucoma. This complementary alliance will support iSTAR Medical's development and commercial efforts for MINIject, as well as provide an opportunity to expand AbbVie's eye care business, building on its glaucoma portfolio which includes drops, sustained release implants, and stent offerings. iSTAR Medical will receive a $60M non-dilutive upfront payment and will continue to develop and commercialize MINIject until completion of the STAR-V clinical study. AbbVie will hold the exclusive right to acquire iSTAR Medical and lead subsequent global development and commercialization of the MINIject device. If AbbVie exercises the right to acquire iSTAR, the stockholders of iSTAR Medical would also be eligible to receive additional contingent payments of up to $475M in a closing payment and upon achievement of certain predetermined milestones. |
Grunenthal, Shionogi | Aug 2022 | 525 | Licensing agreement for resiniferatoxin | Grünenthal and Shionogi have entered into a licensing agreement for Grünenthal's investigational medicine Resiniferatoxin. Shionogi obtained the exclusive rights to commercialise Grünenthal's asset in Japan for pain associated with osteoarthritis of the knee. Shionogi will obtain the exclusive commercialisation rights for RTX in Japan for a total consideration of up to $ 525 million plus additional sales based payments. Shionogi will pay $ 75 million upon signature, and further milestone payments of $ 70 million prior to regulatory approval. The agreement includes competitive investment commitments for launch and commercialisation. Manufacturing and supply of RTX to Shionogi will be carried out exclusively by Grünenthal. |
Bayer, Grunenthal | Jul 2022 | 508.55 | Asset purchase agreement for Nebido | Grünenthal announced an agreement with Bayer to acquire Nebido, the well-known brand for the treatment of male hypogonadism and its associated brands for up to € 500 million. The product is approved and successfully commercialized in over 80 countries. Patent protection exists until March 2024 in the EU and until May 2027 in the US. |
Amgen, Plexium | Feb 2022 | 500 | Collaboration and licensing agreement for targeted protein degradation therapeutics | Amgen and Plexium announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics toward historically challenging drug targets. The multi-year collaboration supports the discovery of novel molecular glue therapeutics leveraging insights from Amgen's expertise in developing multispecific molecules. Under the terms of the agreement, the collaboration will initially focus on two programs with Amgen holding options to add additional programs. Plexium is eligible to receive over $500 million in success-based target access, pre-clinical, clinical, regulatory and commercial milestones, as well as tiered single-digit royalty payments, if all options are exercised. Amgen has a commercial license to each program that advances to a predefined preclinical stage of development and will be responsible for global development and commercialization. The partnership will focus on expanding targeted protein degradation opportunities through discovery of previously unrecognized molecular glues or monovalent degraders. These molecules work through a concept of induced proximity that take advantage of the normal biology of a cell to bring two proteins together to drive protein degradation. This collaboration incorporates Plexium's comprehensive targeted protein degradation platform, powered by a proprietary high-throughput cell-based screening technology that enables the discovery of novel molecular glue therapies. |